ESC Premium Access

GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

Event: ESC CONGRESS 2017
Topic: Diabetes, dysglycaemia and metabolic syndrome
Session type: Satellite Symposium
Sponsored by Novo Nordisk
Date: 28 August 2017
Time: 12:45 - 13:45

Congress Session

4 presentations in this session

Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Speaker: Professor L. Ryden (Stockholm, SE)
Thumbnail

Results from the LEADER cardiovascular outcomes trial.

Speaker: Doctor M. Husain (Toronto, CA)
Thumbnail

Translating trials into practice – Clinical implications .

Speaker: Professor M. Pfeffer (Boston, US)
Thumbnail

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Speaker: Professor L. Ryden (Stockholm, SE)
Speaker: Doctor M. Husain (Toronto, CA)
Speaker: Professor M. Pfeffer (Boston, US)
Thumbnail

6 speakers from this session

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
32 presentations
0 follower

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)
7 presentations
1 follower

Professor Marc Pfeffer

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
23 presentations
0 follower

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
32 presentations
0 follower

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)
7 presentations
1 follower

Professor Marc Pfeffer

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
23 presentations
0 follower

This platform is supported by

logo Novo Nordisk